I have bowel cancer and want to live longer to change my diet

Share This Post

According to a new study by the American Cancer Society, patients with colorectal cancer who eat a healthy diet have a reduced risk of dying from colorectal cancer, even those who improve their diet after diagnosis.

There are more than 1.4 million colorectal cancer (CRC) survivors in the United States. Previous studies have shown that diet quality has a large impact on disease outcomes, and some pre- and post-diagnostic diet ingredients are related to the survival of men and women with CRC Rate related. However, studies of dietary patterns used to assess overall dietary quality related to overall and CRC-specific mortality are inconsistent, making it difficult to develop evidence-based dietary recommendations for CRC survivors.

To learn more, the American Cancer Society postdoctoral research team reviewed the data of 2,801 men and women diagnosed with CRC in the American Cancer Society ’s large prospective cancer prevention study. They found that patients who met the American Cancer Society nutrition and cancer prevention physical activity guidelines before and after diagnosis had lower all-cause and CRC-specific mortality.

The all-cause mortality rate of patients with dietary habits most consistent with the ACS dietary  recommendations was reduced by 22%. A significant decreasing trend was also observed for CRC-specific mortality. For Western dietary patterns of high intake of red meat and other animal products, the risk of CRC death is 30% higher.

Changes in diet after diagnosis are also significantly associated with the risk of death, with a 65% reduction in CRC mortality risk and a 38% reduction in all-cause mortality risk. The results of this study indicate the importance of diet quality as a potentially modifiable tool for improving the prognosis of patients with CRC. These results indicate that a high diet quality after diagnosis, even if it was poor before, may reduce the risk of death.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy